Annovis Bio, Inc. (07X.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, CEO, President & Executive Director | 659.51k | -- | 1951 |
| Mr. Andrew Walsh | Principal Financial Officer | -- | -- | 1989 |
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research & Development | -- | -- | -- |
| Ms. Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations | -- | -- | -- |
| Ms. Melissa Gaines | Senior Vice President of Clinical Operations | -- | -- | -- |
| Mr. Blake Jensen M.B.A. | Head of Quality | -- | -- | -- |
| Ms. Hilda Maibach | Senior Vice President of Statistics | -- | -- | -- |
Annovis Bio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Corporate Governance
Upcoming Events
August 12, 2025 at 8:00 PM UTC - August 18, 2025 at 8:00 PM UTC
Annovis Bio, Inc. Earnings Date
Recent Events
Recent Events Information Not Available